Evidence map›Paper›PMID 39991535›Full record

ArticleClinical case reports2025

A Pedigree With

Zhaoyang Ji, Wenyuan Duan, Jianbo Wu, Mengting Dai, Ping Chen, Jialu Luo, Mingzhi Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhaoyang JiDepartment of Endocrinology and Metabolism, Shulan (Hangzhou) Affiliated Hospital of Shulan International Medical College Zhejiang Shuren University Hangzhou Zhejiang China.ORCID https://orcid.org/0000-0002-5696-2538
Wenyuan DuanRare Disease Center Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College Hangzhou Zhejiang China.
Jianbo WuDepartment of Endocrinology and Metabolism, Shulan (Hangzhou) Affiliated Hospital of Shulan International Medical College Zhejiang Shuren University Hangzhou Zhejiang China.
Mengting DaiZhejiang University of Medicine Hangzhou Zhejiang China.
Ping ChenKey Laboratory of Artificial Organs and Computational Medicine of Zhejiang Province, Shulan (Hangzhou) Hospital, Shulan International Medical College Zhejiang Shuren University Hangzhou China.
Jialu LuoWenzhou Medical University Wenzhou Zhejiang China.
Mingzhi XuDepartment of General Medicine Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences Hangzhou Zhejiang China.ORCID https://orcid.org/0000-0001-6823-7571

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pituitary stalk interruption syndrome is a disease with multiple hormone deficiencies caused by pituitary stalk interruption. Identification of the pathogenic gene variant is helpful for early diagnosis. Early hormone replacement therapy is helpful to improve the prognosis and quality of life of patients.

Indexed as

combined pituitary hormone deficiencyLHX4pituitary stalk interruption syndromeSOX3

Identifiers

PMID39991535
PMCPMC11843472

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.